Antibe Therapeutics Reports on Results of AGM Voting

Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE; OTCQX:ATBPF) is pleased to report the results of the voting on the matters submitted to the annual meeting of shareholders of the Corporation held on October 1, 2014.

The matters voted upon at the meeting and the results of the voting were as follows:

Item 1: Election of Directors

Each of the six nominees proposed by management was elected to serve as a director of the Corporation and to hold office for the ensuing year or until a successor is elected or appointed. The directors are:

Walt MacneeJonathan Ross GoodmanJohn WallaceDan LegaultRoderick FlowerSamira Sakhia

Item 2: Appointment of Auditors

Zeifmans LLP, Chartered Accountants, was appointed the auditors of the Company for the ensuing year at a remuneration to be fixed by the directors of the Company.

Item 3: Amendment of the Stock Option Plan

On a vote by disinterested shareholders, the amended and restated Stock Option Plan of the Corporation as described in the management information circular was approved.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s ATB-346 targets the global need for safer non-steroidal anti-inflammatory drugs (NSAIDs).

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Antibe Therapeutics Inc.Dan Legault, 416-473-4095Chief Executive [e-mail]